Kirilys Therapeutics to Present Preclinical Profile for KRLS-017, a reversible inhibitor of CDK7 for Oncolog December 11, 2023
Kirilys Therapeutics Announces FDA Clearance of IND Application for KRLS-017, a reversible inhibitor of CDK7 for Oncology April 28, 2023
Kirilys Therapeutics Acquires ASN-004, a 5T4-targeting Antibody Drug Conjugate being evaluated in Ph1 Oncology September 1, 2022
Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company March 23, 2022
